Adaptive Biotechnologies (ADPT) Share-based Compensation (2018 - 2026)

Adaptive Biotechnologies has reported Share-based Compensation for 9 years, with the latest figure at $4.8 million in Q1 2026.

• Quarterly Share-based Compensation fell 60.15% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (down 90.59% YoY) and the FY2025 annual result came in at $56.1 million, up 4.61% from the prior year.
• Share-based Compensation slipped to $4.8 million in Q1 2026 per ADPT's latest filing, from $12.7 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $17.3 million in Q2 2023 and troughed at $85893.0 in Q3 2023.
• A 5-year average of $12.7 million and a median of $13.5 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation sank 99.39% in 2023, then soared 15642.84% in 2024.
• Over 5 years, Share-based Compensation stood at $14.3 million in 2022, then gained by 8.83% to $15.6 million in 2023, then decreased by 17.51% to $12.8 million in 2024, then dropped by 0.87% to $12.7 million in 2025, then slumped by 61.94% to $4.8 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $4.8 million, $12.7 million, and $15.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.